ISONICOTINIC acid hydrazide, now officially designated isoniazid, was first synthesized in Germany in 1912 as an exercise for a degree in chemistry.1 Prior to the use of this drug in pulmonary tuberculosis no medical or commercial use was known. Isoniazid was one of over 5,000 drugs tested in vitro and in vivo against Mycobacterium tuberculosis at the Squibb Institute for Medical Research. Isoniazid is marketed under many trade names, among which are Nydrazid, Rimifon, Dinacrin, and INH.*
This report is in three parts: (I) attributes of isoniazid; (II) clinical study of isoniazid in tuberculous uveitis; (III) experimental study of the passage of isoniazid across the blood-aqueous barrier of the rabbit.
I. ATTRIBUTES OF ISONIAZID
—Isoniazid is a pure, colorless, synthetic crystalline compound which is very soluble in water. The general formula is C6H7N3O and the structural formula:The close relationship to nicotinic
SCHLAEGEL TF, HUNGERFORD LN. ISONIAZID IN TUBERCULOUS UVEITIS. AMA Arch Ophthalmol. 1954;51(4):481–498. doi:10.1001/archopht.1954.00920040491008
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: